- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- PDS Implant with Ranibizumab 100 mg/mL
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 69 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 669
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age Related Macular Degeneration
- Interventions
- Referrable versus Non Referral AMD diagnostic test
- Diagnostic Test
- Lead sponsor
- The New York Eye & Ear Infirmary
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Wet Age-Related Macular Degeneration
- Interventions
- PTK787, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Denver, Colorado • Tampa, Florida + 4 more
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Interventions
- bevacizumab, ranibizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 61
- States / cities
- Arcadia, California • Bakersfield, California • Beverly Hills, California + 57 more
- Conditions
- Age-related Macular Degeneration, Geographic Atrophy
- Interventions
- VOY-101
- Biological
- Lead sponsor
- Perceive Biotherapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Brolucizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 9,456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Age Related Macular Degeneration
- Interventions
- ranibizumab, dexamethasone and verteporfin, Ranibizumab
- Drug
- Lead sponsor
- Bay Area Retina Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 87
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
- Conditions
- Dry Age Related Macular Degeneration
- Interventions
- MA09-hRPE
- Biological
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Notal Vision Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Lakewood, Colorado • Orlando, Florida • Cincinnati, Ohio + 2 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- PEGCETACOPLAN (APL-2)
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 792 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 99
- States / cities
- Phoenix, Arizona • Bakersfield, California • Campbell, California + 82 more
- Conditions
- Age Related Macular Degeneration, AMD, CNV
- Interventions
- Efalizumab, Ranibizumab
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Geographic Atrophy
- Interventions
- NGM621
- Biological
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Arcadia, California • Newport Beach, California • Melbourne, Florida + 3 more
- Conditions
- Macular Degeneration
- Interventions
- VEGF Trap
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 8
- States / cities
- Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Lutein-enriched-egg beverage (NWT-02), Placebo
- Dietary Supplement
- Lead sponsor
- Newtricious R&D BV
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more
- Conditions
- Macular Degeneration
- Interventions
- pegaptanib sodium
- Drug
- Lead sponsor
- Eyetech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Bridgeport, Connecticut • Hamden, Connecticut + 16 more
- Conditions
- Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion
- Interventions
- Ocriplasmin, Sham injection
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Sacramento, California • Aurora, Colorado + 9 more
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- smaller incision, new generation implantable miniature telescope (SING-IMT)
- Device
- Lead sponsor
- VisionCare, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Loma Linda, California • Long Beach, California • Sarasota, Florida + 7 more
- Conditions
- Choroid Neovascularization, Age-Related Macular Degeneration
- Interventions
- AGN 211745, Ranibizumab 500µg
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Fovista™, Lucentis®, Avastin®, Eylea®
- Drug
- Lead sponsor
- Retinal Consultants of Arizona
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Brolucizumab, Aflibercept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Huntington Beach, California + 51 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AIV007
- Drug
- Lead sponsor
- AiViva BioPharma, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Huntington Beach, California • Abilene, Texas